Product Description
HMBD-501 represents a potentially best-in-class HER3-ADC combining Hummingbird Bioscience’s data-rich, systems biology approach to rational antibody discovery with state-of-the-art bioconjugation technologies. (Sourced from: https://hummingbirdbioscience.com/hmbd-501/)
Mechanisms of Action: ERBB3 Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hummingbird Bioscience
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|